Related Experiment Videos
Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells
T G Hullinger1, R S Taichman, D A Linseman
1Department of Pharmacology, University of Michigan, School of Medicine, Ann Arbor, Michigan 48109, USA.
Abstract:
Tumor cells frequently have pronounced effects on the skeleton including bone destruction, bone pain, hypercalcemia, and depletion of bone marrow cells. Despite the serious sequelae associated with skeletal metastasis, the mechanisms by which tumor cells alter bone homeostasis remain largely unknown. In this study, we tested the hypothesis that the disruption of bone homeostasis by tumor cells is due in part to the ability of tumor cells to upregulate osteopontin (OPN) mRNA in osteoblasts. Conditioned media were collected from tumor cells that elicit either osteolytic (MCF-7, PC-3) or osteoblastic responses (LNCaP) in animal models and their effects on OPN gene expression were compared using an osteoblast precursor cell line, MC3T3-E1 cells. Secretory products from osteolytic but not osteoblastic tumor cell lines were demonstrated to upregulate OPN in osteoblasts while inhibiting osteoblast proliferation and differentiation. Signal transduction studies revealed that regulation of OPN was dependent on both protein kinase C (PKC) and the mitogen-activated protein (MAP) kinase cascade. These results suggest that the upregulation of OPN may play a key role in the development of osteolytic lesions. Furthermore, these results suggest that drugs that prevent activation of the MAP kinase pathway may be efficacious in the treatment of osteolytic metastases.
Insights
Tumor cells can disrupt bone health by increasing osteopontin (OPN) in bone cells. Targeting the mitogen-activated protein (MAP) kinase pathway may help treat bone destruction from cancer metastasis.
Area of Science:
- Oncology
- Skeletal Biology
- Cell Signaling
Background:
- Tumor cells significantly impact bone, causing destruction and pain, but mechanisms are unclear.
- Skeletal metastasis leads to severe complications, including bone loss and marrow depletion.
- Understanding how tumor cells alter bone homeostasis is crucial for developing effective treatments.
Purpose of the Study:
- To investigate if tumor cells upregulate osteopontin (OPN) mRNA in osteoblasts, contributing to bone homeostasis disruption.
- To determine the role of tumor cell secretory products in modulating OPN expression and osteoblast function.
- To identify the signaling pathways involved in tumor cell-induced OPN regulation.
Main Methods:
- Collected conditioned media from osteolytic (MCF-7, PC-3) and osteoblastic (LNCaP) tumor cell lines.
- Assessed the effects of conditioned media on OPN gene expression in osteoblast precursor cells (MC3T3-E1).
- Investigated signal transduction pathways, including protein kinase C (PKC) and mitogen-activated protein (MAP) kinase cascades.
Main Results:
- Secretory products from osteolytic tumor cells, but not osteoblastic cells, upregulated OPN in osteoblasts.
- Osteolytic tumor cell products inhibited osteoblast proliferation and differentiation.
- OPN regulation was dependent on both PKC and MAP kinase signaling pathways.
Conclusions:
- Upregulation of osteopontin (OPN) by tumor cells may be a key factor in developing osteolytic bone lesions.
- Inhibiting the MAP kinase pathway could be a potential therapeutic strategy for treating osteolytic metastases.
- Further research into tumor cell-bone interactions can reveal novel therapeutic targets.